Product Candidate

Thymosin Beta-4 (Tβ4): A Peptide Candidate Under Evaluation for Regenerative and Anti-inflammatory Biology

Thymosin beta-4 (Tβ4) is a naturally occurring, water-soluble peptide implicated in actin dynamics and repair-associated cellular responses. Through actin binding and downstream effects on cell migration, Tβ4 has been studied in experimental systems relevant to tissue repair, vascular remodeling, and injury-associated inflammation. Reported findings across preclinical models include effects consistent with progenitor-cell–associated responses, angiogenesis, and modulation of wound remodeling processes, including pathways linked to fibrosis and scar formation.

The therapeutic rationale for Tβ4 has been discussed across multiple disease contexts. A review published in 2020 summarized evidence supporting its potential relevance to cardiac injury and repair (1), and additional literature has explored applications in ocular surface disorders, metabolic disease–associated tissue injury, and chronic wounds.

Björklund Pharma AS is evaluating the therapeutic and commercial potential of Tβ4 with a programmatic focus on defined indications characterized by tissue injury, impaired repair, and inflammatory remodeling. Indication prioritization and any future clinical direction are intended to be guided by translational feasibility and the strength of preclinical and clinical evidence.

Reference

1. Bjørklund G, Dadar M, Aaseth J, Chirumbolo S. Thymosin β4: a multi-faceted tissue repair stimulating protein in heart injury. Curr Med Chem 2020; 27(37): 6294-6305.